PARP inhibitors: Treating mCRPC from a genetic basis
Treatments provide a targeted therapeutic strategy for metastatic castration-resistant prostate cancer.
Adding lutetium (177Lu) vipivotide tetraxetan to SOC improves rPFS in mHSPC
Lower-dose abiraterone offers viable alternative to standard-dose for mCRPC
Long-term data support radium-223 safety in mCRPC
Survey: New NMIBC treatments face slow uptake